In Springview Capital Management’s Q2 2023 letter, Haleon (LON:HLN, Financial) was identified as a new core position, valued for its strong brand portfolio and growth potential. Despite trading at a discount due to temporary overhangs, the fund sees significant upside as these issues are resolved.
"UK-based Haleon is a pure-play global consumer-health company that owns trusted brands like Advil, Excedrin, Centrum, Sensodyne, and Theraflu. Haleon has an attractive financial profile and an experienced management team. The stock trades at less than 17x next year’s earnings, a big discount to more well-known public peers like P&G, Colgate, and Church & Dwight. Given HLN’s superior business quality and growth prospects, we think this valuation disconnect is unwarranted. In fact, we think HLN deserves to trade at a premium considering its above-average margins, returns, and organic growth profile." — Springview Capital Management, Q2 2023 Fund Letter
Read full letter at gurufocus Springview Capital Management 2023 Q2 page.
